METHODS: We identified a retrospective cohort of patients who underwent MRI prior to radical prostatectomy with both MRI visible (PIRADS 3 -5) and invisible PCa. MRI for each patient was re-reviewed and co-registered with whole-mount histopathology. DNA and RNA were co-isolated from all tumor foci pre-identified on formalin-fixed paraffin-embedded specimens. High depth, targeted DNA and RNA next generation sequencing was performed to characterize the molecular profile of each tumor focus using the Oncomine Comprehensive Panel (DNA) and a custom targeted RNAseq panel assessing PCa relevant alterations. A multigene RNAseq model was developed and validated in two independent cohorts to predict MRI visible PCa and to determine the prognostic significance of MRI visibility.
INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) screening mainly relies on prostate-specific antigen (PSA). However, the lack of specificity of PSA testing leads to an unnecessary biopsy. Indeed, although the United States Preventive Services Task Force (USPSTF) assigned a grade of C to PSA-based screening for men aged 55 to 69 years, the USPSTF recommends against PSA-based screening for men !70 years. The presence of circulating miRNA can potentially offer crucial information about cancerous conditions in a less-invasive manner. In this study, we aimed to establish a model based on a combination of circulating miRNAs to detect PCa in men with suspected PCa with high sensitivity and specificity by using large-scale miRNA microarray analyses.
METHODS: To develop an optimal diagnostic model, we examined comprehensive miRNA profiles of 809 serum samples of PCa patients, 241 of negative prostate biopsy patients and 41 of healthy controls using microarray. We divided them into 3 groups, discovery set (N[82), training set (N[484) and validation set (N[484) . The discovery set was used to identify candidate miRNAs for PCa detection, and the training set was used to construct a diagnostic model using combinations of candidate miRNAs. Finally, the performance of the diagnostic model was evaluated in the validation set.
RESULTS: In the discovery set, we identified 16 miRNAs that were upregulated, and 2 miRNAs that were downregulated in PCa samples. In training set, a robust diagnostic model was constructed based on expression level of two miRNAs in training set, and the diagnostic performance of it was validated in the validation set with a sensitivity of 0.90, a specificity of 0.90, and an area under the curve (AUC) of 0.95. In addition, regardless of the patients' stage, the diagnostic model showed high sensitivity.
CONCLUSIONS: The present study is the largest scale study performed to date, and the results indicated that evaluation of circulating miRNAs is a feasible method for detecting PCa in men with suspected PCa. Our established model would help us improve the diagnosis of PCa and reduce unnecessary biopsy of the prostate. METHODS: Trainees were defined as urologists in practice for less than one year. We reviewed the charts of men on whom trainee urologists educated at our hospital had performed TPB between 2015 and 2018, recording procedure time, presence or absence of cancer, and complications. Local anesthesia was ensured using subcutaneous anesthesia for perineal and periapical triangle blocks. Systematic 14-core TPB was performed with magnetic resonance imaging (MRI)-targeted biopsy (four cores per targeted lesion). Men undergoing targeted biopsy alone were excluded from this analysis. We evaluated the learning curves and outcomes of TPB, and compared them with outcomes of TPB performed by senior urologists as controls.
RESULTS: Three trainees performed 115 procedures (50 by MK over 12 months, 34 by KT over 9 months, and 31 by HS over 6 months) and three senior urologists performed 121 procedures. There was no significant difference in age, prostate-specific antigen, or MRI positivity rates between trainees 0 and senior urologists 0 patients. The median TPB times were 13/9 minutes for trainees/senior urologists (p<0.01). TPB times of trainees shortened over time to match those of senior urologists during the learning curve (Figure) . There was no difference in cancer detection rates between trainees and senior urologists (73% and 68%, respectively, P[0.39). No infectious complications occurred in either group. Urinary retention was observed in two cases in each group (1.7%/1.7%) and vagal reflex was observed in one trainee case.
CONCLUSIONS: Trainees achieved procedure times equivalent to those of senior urologists within 30-50 procedures. Cancer detection rates and complication rates were comparable between trainees 0 and senior urologists 0 cases during the learning curve.
